Inventor
Jeffrey Charles Way
Inventor
Cambridge, MA, US
Overview
Patents· 27 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations22%
A61KPreparations for medical, dental or toiletry purposes19%
C12NMicroorganisms or enzymes10%
Y02ATechnologies for adaptation to climate change9%
G01NInvestigating or analysing materials by determining their chemical or physical properties8%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests3%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2%
C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture1%
C12YEnzymes1%
PatentTitleYear
11,059,874Engineered opsonin for pathogen detection and treatment202111,059,873Engineered opsonin for pathogen detection and treatment202111,014,973Fusion proteins for treating cancer and related methods202110,907,221Engineered genetic enteric sensor bacteria and uses thereof202110,865,235Engineered microbe-targeting molecules and uses thereof202010,703,824Internalizing moieties202010,538,566Fusion proteins for treating cancer and related methods202010,538,562Engineered opsonin for pathogen detection and treatment202010,526,399Engineered microbe-targeting molecules and uses thereof202010,385,367Methods and molecules for yield improvement involving metabolic engineering201910,308,697Fusion proteins for treating cancer and related methods201910,221,250Internalizing moieties201910,047,405Engineered genetic enteric sensor bacteria and uses thereof201810,017,581Methods and compositions for treatment of Pompe disease20189,593,160'Engineered microbe-targeting molecules and uses thereof'20179,150,631'Engineered opsonin for pathogen detection and treatment'20158,926,973'Reducing the immunogenicity of fusion proteins'20158,536,308'Antibodies to interleukin-6'20138,066,994'Proteins comprising an IgG2 domain'20117,973,150'Reducing the immunogenicity of fusion proteins'20117,820,155'Methods of treating cancer comprising administering an interleukin-6 antibody variable region'20107,615,217'Artificial proteins with reduced immunogenicity'20097,601,814'Reducing the immunogenicity of fusion proteins'20097,589,179'IL-7 variants with reduced immunogenicity'20097,211,253'Erythropoietin forms with improved properties'20077,189,830'Anti-KSA/IL-2 fusion proteins with reduced immunogenicity'20076,465,192'Compounds and methods for the inhibition of protein-protein interactions'2002Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2002–2019Patents assigned to WAY JEFFREY C (3)· patent assignee history
2002–2021Based in Cambridge, MA, US· patent location history
2007–2015Patents assigned to MERCK PATENT GMBH (9)· patent assignee history
2011–2015Patents assigned to WAY JEFFREY (3)· patent assignee history
2015–2021Patents assigned to HARVARD COLLEGE (12)· patent assignee history
2018–2020Patents assigned to VALERION THERAPEUTICS LLC (3)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| HARVARD COLLEGE | 12 | 2015–2021 |
| MERCK PATENT GMBH | 9 | 2007–2015 |
| VALERION THERAPEUTICS LLC | 3 | 2018–2020 |
| WAY JEFFREYself | 3 | 2011–2015 |
| WAY JEFFREY Cself | 3 | 2002–2019 |
Locations
| Location | Patents | Span |
|---|---|---|
| Cambridge, Massachusetts, US | 27 | 2002–2021 |